135 related articles for article (PubMed ID: 21356164)
21. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
Loupakis F; Vasile E; Santini D; Masi G; Falcone A; Graziano F
Pharmacogenomics; 2008 Jan; 9(1):55-69. PubMed ID: 18154448
[TBL] [Abstract][Full Text] [Related]
22. [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].
Shimodaira H; Soeda H; Komine K; Ishioka C
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1063-6. PubMed ID: 19620792
[TBL] [Abstract][Full Text] [Related]
23. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.
Dokala A; Thakur SS
Oncogene; 2017 Apr; 36(17):2337-2344. PubMed ID: 27775071
[TBL] [Abstract][Full Text] [Related]
24. Erbitux diagnostic latest adjunct to cancer therapy.
Mitchell P
Nat Biotechnol; 2004 Apr; 22(4):363-4. PubMed ID: 15060535
[No Abstract] [Full Text] [Related]
25. Translating the molecular analysis of cancer biology into therapeutic concepts.
Mader RM; Brodowicz T; Zielinski CC
Cancer Biomark; 2014; 14(2-3):87-91. PubMed ID: 24878809
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA: future perspectives in colorectal cancer.
Altomare DF; Di Lena M; Giuratrabocchetta S
Colorectal Dis; 2012 Feb; 14(2):133-4. PubMed ID: 22233118
[No Abstract] [Full Text] [Related]
27. Anti-EGFR Agents: Current Status, Forecasts and Future Directions.
Kwapiszewski R; Pawlak SD; Adamkiewicz K
Target Oncol; 2016 Dec; 11(6):739-752. PubMed ID: 27515815
[TBL] [Abstract][Full Text] [Related]
28. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.
Thomas R; Weihua Z
Front Oncol; 2019; 9():800. PubMed ID: 31508364
[TBL] [Abstract][Full Text] [Related]
29. Colorectal cancer molecular biology moves into clinical practice.
Pritchard CC; Grady WM
Gut; 2011 Jan; 60(1):116-29. PubMed ID: 20921207
[TBL] [Abstract][Full Text] [Related]
30. Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention.
Pabla B; Bissonnette M; Konda VJ
World J Clin Oncol; 2015 Oct; 6(5):133-41. PubMed ID: 26468449
[TBL] [Abstract][Full Text] [Related]
31. EGFR Signaling in Colorectal Carcinoma.
Krasinskas AM
Patholog Res Int; 2011 Feb; 2011():932932. PubMed ID: 21403829
[TBL] [Abstract][Full Text] [Related]
32. Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
Park DG
J Korean Soc Coloproctol; 2011 Jun; 27(3):103-4. PubMed ID: 21829762
[No Abstract] [Full Text] [Related]
33. Is placental alkaline phosphatase (PLAP) a useful marker for seminoma?
Nielsen OS; Munro AJ; Duncan W; Sturgeon J; Gospodarowicz MK; Jewett MA; Malkin A; Thomas GM
Eur J Cancer; 1990; 26(10):1049-54. PubMed ID: 2148879
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
35. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
37. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
Mohan S; Heitzer E; Ulz P; Lafer I; Lax S; Auer M; Pichler M; Gerger A; Eisner F; Hoefler G; Bauernhofer T; Geigl JB; Speicher MR
PLoS Genet; 2014 Mar; 10(3):e1004271. PubMed ID: 24676216
[TBL] [Abstract][Full Text] [Related]
38. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
39. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy.
Kawamura M; Saigusa S; Toiyama Y; Tanaka K; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
Anticancer Res; 2012 Apr; 32(4):1527-31. PubMed ID: 22493396
[TBL] [Abstract][Full Text] [Related]
40. CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.
Mendelsohn J; Prewett M; Rockwell P; Goldstein NI
Clin Cancer Res; 2015 Jan; 21(2):227-9. PubMed ID: 25593342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
